Status:
TERMINATED
Pharmacokinetic Interaction Between AZD3480 and Donepezil
Lead Sponsor:
AstraZeneca
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
20-60 years
Phase:
PHASE1
Brief Summary
The aims of this study are to 1) examine the effects of AZD3480 and donepezil on the blood concentrations of each other and 2) assess the safety and tolerability of the combined administration of AZD3...
Eligibility Criteria
Inclusion
- Provision of informed consent prior to any study-specific procedures
- BMI between 18 and 30 kg/m2
- Medical and surgical history and physical examination without any clinically significant findings
- Genotyped as an EM, defined in this study as having ≥ 1.5 functional CYP2D6 alleles, or a PM, defined as having zero functional CYP2D6 alleles
Exclusion
- History of clinically significant cardio- or cerebrovascular, pulmonary, renal, hepatic, neurological, mental or gastrointestinal disorder or any other major disorder that may interfere with the objectives of the study, as judged by the Investigator
- Clinically significant illness as judged by the Investigator, within two weeks before the first administration of investigational product
- Female subjects who have a positive pregnancy test or who are pregnant or breast-feeding
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00713765
Start Date
December 1 2008
End Date
December 1 2008
Last Update
August 15 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Manchester, United Kingdom